louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04999722: Establishment and Preliminary Evaluation of Digital Three Level Linkage Whole Process Diabetes Management System
Official title: Establishment and Preliminary Evaluation of Digital Three Level Linkage Whole Process Diabetes Management System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus
Keywords: Diabetes Mellitus
Manage
Mobile app
Lead sponsor: Chongqing Renji Hospital, University of Chinese Academy of Sciences
Sponsor class: OTHER_GOV
First posted: 2021-08-11
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Mobile app was used for follow-up
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study used Nan'an District of Chongqing, China as a pilot project to improve the comprehensive compliance rate of diabetic patients in China, and reduce the physical and economic harm caused by complications.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of type 2 diabetes.
2. Aged 18-70;
3. HbA1c ≥ 8.0%

Exclusion Criteria:

1. Pregnancy;
2. Chronic kidney disease (CKD stage 5);
3. Senile dementia patients;
4. With malignant tumor;
5. Moderate and severe anemia;
6. Severe liver dysfunction;
7. Hemolytic anemia, aplastic anemia, massive blood loss or transfusion, chronic malaria;
8. In the recent one week, large doses of salicylate, erythropoietin, antiretroviral drugs, ribavirin and other drugs that have an impact on the detection of glycosylated hemoglobin were used

Primary outcomes:
measure: Change from Baseline Glycated hemoglobin at 12 months
timeFrame: Month 12
Secondary outcomes:
measure: Change from Baseline Blood pressure at 12 months
timeFrame: Month 12
measure: Change from Baseline blood lipid at 12 months
timeFrame: Month 12
measure: Change from Baseline Diabetic nephropathy at 12 months
timeFrame: Month 12
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00531622: An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
Official title: An Eight-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Saredutant 100 mg Once Daily in Combination With Escitalopram 10 mg Once Daily in Patients With Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Major Depressive Disorder
Keywords: Depression
Major Depressive Episode
Antidepressant
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-09-19
Enrollment: 643
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).


Eligibility criteria: Inclusion Criteria:

* Outpatients with recurrent Major Depressive Disorder

Exclusion Criteria:

* Symptoms of current depressive episode for less than 30 days or more than 2 years
* Mild depression, as measured by standard clinical research scales
* Significant suicide risk
* Lack of sexual activity (including masturbation)
* Other psychiatric conditions that would obscure the results of the study
* History of failure to respond to antidepressant treatment
* Pregnancy or breast-feeding

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Change from baseline to Day 56 in Hamilton depression rating scale (HAM-D) total score
timeFrame: Baseline, Day 56
measure: Change from Baseline to Day 56 in the CGI-S Severity of Illness score
timeFrame: Baseline, Day 56
Secondary outcomes:
measure: Change from baseline to Day 56 in the Clinical Global Impression (CGI) severity of illness score
timeFrame: Baseline, Day 56
measure: Change from baseline to Day 56 in HAM-D depressed mood item scores.
timeFrame: Baseline, Day 56
measure: Percentage of patients demonstrating a treatment response
timeFrame: Day 56
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis Administrative Office
state: New Jersey
city: Buenos Aires
country: Argentina
facility: Sanofi-Aventis Administrative Office
city: Helsinki
country: Finland
facility: Sanofi-Aventis Administrative Office
city: Paris
country: France
facility: Sanofi-Aventis Administrative Office
city: Mexico
country: Mexico
facility: Sanofi-Aventis Administrative Office
city: Bromma
country: Sweden
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: ICD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06987422: Plantar Fascia and Achilles Tendon Thickness and Flexibility in Pes Planus
Official title: Investigation of Plantar Fascia and Achilles Tendon Thickness and Flexibility in Individuals With Pes Planus
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pes Planus
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2025-05-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with Pes Planus

Brief summary: The aim of this study is to examine the plantar fascia and Achilles tendon thickness and flexibility in individuals with pes planus. Individuals between the ages of 18-45 who have been diagnosed with pes planus by an orthopedist and healthy individuals with similar demographic characteristics will be included in the study as a control group. Demographic information of the individuals will be recorded and clinical evaluations will be made. The foot posture of the individuals participating in the study will be evaluated with the Foot Posture Index, and the degree of flat feet will be evaluated with the Navicular Drop Test. The Achilles tendon and plantar fascia thicknesses of the individuals participating in the study will be measured with ultrasound, and the plantar fascia and Achilles tendon flexibility will be measured with a myotonometer.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 45
* Mini Mental State Examination (MMSE) score of 24 to 30
* Diagnosed with Pes Planus by a physician

Exclusion Criteria:

* Inability to communicate verbally
* Use of walking aids
* Any history of surgery involving the lower extremities
* People with severe visual impairment, neurological disorders and/or congestive heart failure.

Primary outcomes:
measure: Foot Posture Index
timeFrame: Baseline
measure: Navicular Drop Test
timeFrame: Baseline
measure: Ultrasonographic Evaluation
timeFrame: Baseline
measure: Myotonometer
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Atılım University
Study officials:
affiliation: Atılım University
name: Süleyman Korkusuz, PhD
role: STUDY_CHAIR
References:
citation: Angin S, Crofts G, Mickle KJ, Nester CJ. Ultrasound evaluation of foot muscles and plantar fascia in pes planus. Gait Posture. 2014;40(1):48-52. doi: 10.1016/j.gaitpost.2014.02.008. Epub 2014 Feb 26.
citation: Tas S, Aktas A, Dikici TF, Cekok FK. Achilles Tendon, Patellar Tendon, and Femoral Cartilage Thickness in Control vs Asymptomatic Flatfoot Young Adults. Foot Ankle Int. 2023 Jan;44(1):81-88. doi: 10.1177/10711007221136137. Epub 2022 Nov 22.
Clinical trial NCT02129322: Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Official title: Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2014-05-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation


Eligibility criteria: Inclusion Criteria:

* hepatocellular carcinoma after liver transplantation
* Major organ (heart, lung and brain) function was normal

Exclusion Criteria:

* Any active infectious process
* The presence of clinically confirmed extrahepatic metastasis
* Postoperative dysfunction of any organ

Primary outcomes:
measure: Time to Recurrence (TTR)
timeFrame: within five years after liver transplantation
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: within the five years after liver transplantation
Other outcomes:
measure: Circulative tumor cell (CTC) level change
timeFrame: within one year after liver transplantation
Locations:
city: Hangzhou
country: China
facility: First affiliated hospital, Zhejiang University
Study officials:
affiliation: First Affiliated Hospital,Zhejiang University
name: Weijia fang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00721422: A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
Official title: A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Renal Insufficiency
Pharmacokinetics
Keywords: Pharmacokinetics of PD 0332334 in subjects with renal insufficiency
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-07-24
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: 1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body.
2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function.

Detailed description: Additional Study Purpose Details: Investigation of the pharmacokinetics, safety, and tolerability of a single dose of PD 0332334 in patients with impaired renal function.

On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

Eligibility criteria: Inclusion Criteria:

Healthy volunteers OR subjects with kidney impairment

Exclusion Criteria:

1. Receiving hemodialysis
2. clinically significant or unstable medical disease other than kidney disease

Primary outcomes:
measure: maximum plasma concentration (Cmax), time of maximum plasma concentration (Tmax), and apparent clearance from plasma (CL/F)
timeFrame: 1 day
measure: amount of PD 0332334 eliminated unchanged in urine during the 96-hour collection period (Ae96)
timeFrame: 5 days
measure: PD 0332334 area under the curve from 0 to infinity (AUCinf), PD 0332334 area under the curve from 0 to last quantifiable concentration (AUClast),
timeFrame: 5 to 17 days depending on cohort
measure: PD 0332334 renal clearance (CLr), apparent volume of distribution (Vz/F), terminal half life (t1/2),
timeFrame: 5 to 17 days depending on cohort
Secondary outcomes:
measure: Adverse events, ECG, physical exams, clinical safety laboratory, and vital signs
timeFrame: 5 to 17 days
Other outcomes:
Locations:
city: Cypress
country: United States
facility: Pfizer Investigational Site
state: California
city: Miami
country: United States
facility: Pfizer Investigational Site
state: Florida
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01946022: Evaluation of Granulosa Cells Function After IVF Protocols
Official title: In Vitro Evaluation of Luteinized Granulosa Cells After Being Submitted to in Vitro Fertilization Protocols With Gonadotropin-Releasing Hormone (GnRH) Agonist and GnRH Antagonist
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
In Vitro Fertilization Protocols
Keywords: infertility
ovulation induction
luteal phase
granulosa cells function
GnRH agonist and antagonist
HMG
FSHr
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
First posted: 2013-09-19
Enrollment: 28
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study is intended to evaluate ovarian cells after being submitted do different in vitro fertilization protocols. The investigators will analyze hormones secretion and intracellular mechanisms of these cells comparing the GnRH agonist protocol and the GnRH antagonist protocol.


Eligibility criteria: Inclusion Criteria:

* Patient age limit: 39 years
* Follicle Stimulating Hormone (FSH) \< 10 micrometer (mU) / Liter
* Antral follicular count \> 12
* Regular menses (25 to 35 days)
* More than 3 oocytes after ovarian punction
* Anti Mullerian between 1 e 3 ng/ml

Exclusion Criteria:

* Patients submitted to intracytoplasmatic sperm injection (ICSI)
* Ovarian mass or cyst
* Clinical / endocrine pathologies

Primary outcomes:
measure: Evaluation of steroid secretion and enzyme expression in in vitro luteinized granulosa cells
timeFrame: after 48h in media culture
measure: Number of retrieved oocytes
timeFrame: After the ovarian punction
Secondary outcomes:
measure: number of embryos
timeFrame: 3 to 5 days after ovarian punction
measure: Subgroup analyses comparing FSH versus HMG protocols
timeFrame: after ovarian punction
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Projeto Cegonha
state: RS
city: Porto Alegre
country: Brazil
facility: Insemine
state: RS
Study officials:
References:
Clinical trial NCT06388122: DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Official title: DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: HER2-negative Breast Cancer
Hormone-receptor-positive Breast Cancer
Metastatic Breast Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-04-29
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult female patients \> 18 years old with diagnosis of metastatic HR positive HER2 negative breast cancer that will be or are currently being treated with standard of care endocrine therapy +/- CDK 4/6 inhibitors.

Brief summary: The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.


Eligibility criteria: Inclusion Criteria:

* Pre- or post-menopausal HR+ metastatic breast cancer patients who are:

  * Group 1: scheduled to initiate 1st line combination therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ metastatic breast cancer (mBC).
  * Group 2: scheduled to initiate second or later lines of therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) with or without an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC.
  * Group 3: currently receiving 1st line therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC.
  * Group 4: scheduled to initiate, or are currently receiving, 1st or 2nd line therapy of an FDA approved endocrine therapy (single agent) for pre- or post-menopausal HR+ mBC.

NOTE: Patients that meet eligibility criteria for any of the above groups that are already enrolled in an ongoing clinical trial are eligible for co-enrollment to this observational study.

Exclusion Criteria:

* Treatment including investigational agent or therapies
* Early breast cancer diagnosis
* Male breast cancer
* Currently receiving treatment for other active malignancy at time of registration

  * EXCEPTIONS: Nonmelanoma skin cancer or carcinoma-in-situ (e.g. of cervix, prostate)
* Inability to give written informed consent

Primary outcomes:
measure: DiviTum®TKa assay as an early predictor of primary treatment resistance
timeFrame: Every cycle (approximately 28 days) until disease progression up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Pooja Advani, MBBS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00821522: The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery
Official title: The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Kidney Insufficiency
Acute Renal Insufficiency
Acute Kidney Injury
Ischemic Preconditioning
Keywords: Acute Kidney Insufficiency
Acute Renal Insufficiency
Acute Kidney Injury
Cardiac Surgical Procedures
Ischemic Preconditioning
Lead sponsor: MaineHealth
Sponsor class: OTHER
Collaborators: name: MaineHealth
First posted: 2009-01-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Acute kidney injury is associated with cardiopulmonary bypass during heart surgery and its pathogenesis is similar to that of ischemia-reperfusion injury. Remote ischemic preconditioning attenuates myocardial ischemia-reperfusion injury in patients undergoing coronary bypass surgery. The investigators hypothesize that such preconditioning reduces the incidence of acute kidney injury associated with cardiopulmonary bypass.


Eligibility criteria: Inclusion Criteria:

* Patient undergoing heart surgery on cardiopulmonary bypass.

Exclusion Criteria:

* Known peripheral vascular disease of the lower extremities associated with active skin necrosis or infection.
* End-stage renal disease.
* Inability to give informed consent.

Primary outcomes:
measure: Incidence of acute kidney injury, after surgery, as defined by elevation in serum creatinine greater than or equal to 0.3 mg/dl.
timeFrame: 48 hours after surgery.
Secondary outcomes:
measure: Oliguria.
timeFrame: 12 hours after surgery.
measure: Incidence of acute kidney injury as defined by post-operative elevation in NGAL.
timeFrame: 3 hours after cardiopulmonary bypass.
Other outcomes:
Locations:
city: Portland
country: United States
facility: Maine Medical Center
state: Maine
Study officials:
affiliation: MaineHealth
name: Robert F Zimmerman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02099422: Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome
Official title: The Randomized TOPIC Study : Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Coronary Stenting
Antiplatelet Therapy
Lead sponsor: Hôpital de la Timone
Sponsor class: OTHER
First posted: 2014-03-28
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ACS treated by coronary stent implantation

Brief summary: Comparison of two antiplatelet strategies between months 1 and 12 after coronary stenting for ACS. Efficiency and tolerance évaluation


Eligibility criteria: Inclusion Criteria:

* ACS and coronary stenting one month ago

Exclusion Criteria:

* age under 18 and pregnancy

Primary outcomes:
measure: combined ischemic and hemorragic endpoint
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: CHU Timone hospital . Sc CARDIOLOGIE. Rue saint Pierre.
Study officials:
References:
Clinical trial NCT06785922: Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori
Official title: Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Gastric Microbiota
Helicobacter Pylori
CagA
Gastric Cancer
Keywords: Gastric microbiota
Helicobacter pylori
CagA
Gastric cancer
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2025-01-21
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this clinical trial is to study the differences in gastric microbiota (Diversity index) between patients who were infected with CagA-positive Helicobacter pylori and CagA-negative Helicobacter pylori. The main question it aims to answer are:

The effect of Helicobacter pylori typing (CagA status) on gastric microbiota, what is the different?

Patients indicated for EGD at Siriraj Endoscopic Center will undergo a Helicobacter pylori test (Rapid urease test) If the result is positive, a stomach biopsy for gastric microbiota testing and CagA antibody testing will be conducted. Then, the patients will be divided into two groups: CagA-positive Helicobacter pylori and CagA-negative Helicobacter pylori.

To compare the differences in gastric microbiota in terms of species and biodiversity, as well as endoscopic results, etc.


Eligibility criteria: Inclusion Criteria:

* Patients aged over 18 with an indication for EGD
* Helicobacter pylori infection (Rapid urease test positive)

Exclusion Criteria:

* Severe comorbidities: poorly controlled DM, ESRD, decompensated cirrhosis, Malignancy
* BMI ≤ 23 kg/m2
* Receiving medications that affect the gastric microbiota include Antibiotics, probiotics, or bismuth within 4 weeks, PPI within 2 weeks, NSAIDs or Metformin within 2 weeks
* History of cholecystectomy or proximal small bowel surgery

Primary outcomes:
measure: The differences in gastric microbiota (Diversity index)
timeFrame: On the 1 day of EGD
Secondary outcomes:
measure: Microbiota composition
timeFrame: On the 1 day of EGD
measure: Endoscopic finding
timeFrame: During the EGD
measure: Pathological finding
timeFrame: Within 2 week after EGD
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Faculty of internal medicine siriraj hospital, Mahidol university
state: Bangkok
Study officials:
References: